hold on there's just too much going on in Congress lmao...
Requires more drug supply chain info and original manufacturer labeling.
Sponsors: Reps. Matsui (D-CA), Crenshaw (R-TX), Schrier (D-WA), Hinson (R-IA).
In committee, no House vote yet
This bill proposes changes to federal law, requiring drug manufacturers to provide more detailed reports about their supply chains, including suppliers of active ingredients. It also mandates that drug labels include information about the original manufacturer. The bill was introduced by a bipartisan group of representatives and referred to the House Energy and Commerce Committee, where it awaits consideration.
Introduced Apr 16, 2026
The bill was introduced in the House of Representatives on April 16, 2026. It has been referred to the Committee on Energy and Commerce. For the bill to become law, it must first be approved by this committee, then pass a vote in the full House. After that, it would move to the Senate for similar approval, and finally, be signed by the President.
If this bill becomes law, the labels on your prescription and over-the-counter drugs, as well as their active ingredients, could start including the name and location of their original manufacturer. This additional information could help pharmacists and healthcare providers understand a drug's full supply chain. Federal regulators would also receive more frequent and detailed reports on drug manufacturing, potentially improving their ability to monitor supply chain stability and identify origins.
Supporters Say
Supporters believe this bill increases transparency and strengthens the reliability of drug supply chains.
Critics Say
Critics might argue it creates burdensome reporting for drug makers or adds costs to manufacturing.
Those in favor would likely highlight the importance of knowing the origins of medications to ensure safety and quality, especially in a global supply chain. Opponents might raise concerns about the logistics and costs for pharmaceutical companies to implement new reporting and labeling requirements, suggesting it could impact drug pricing or availability.